Molecular alterations in endometrial and ovarian clear cell carcinomas: Clinical impacts of telomerase reverse transcriptase promoter mutation

Modern Pathology

Volumn 28, Issue 2, 2015, Pages 303-311

  Huang, Hsien Neng ^a,b   Chiang, Ying Cheng ^c   Cheng, Wen Fang ^c   Chen, Chi An ^c   Lin, Ming Chieh ^b   Kuo, Kuan Ting ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

RETINOBLASTOMA BINDING PROTEIN 2; TELOMERASE REVERSE TRANSCRIPTASE; ARID1A PROTEIN, HUMAN; NUCLEAR PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; TELOMERASE; TERT PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CLEAR CELL CARCINOMA; DISEASE FREE SURVIVAL; ENDOMETRIUM CANCER; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; ADENOCARCINOMA; ENDOMETRIUM TUMOR; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MOLECULAR GENETICS; MORTALITY; MUTATION; NUCLEOTIDE SEQUENCE; OVARY TUMOR; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA, CLEAR CELL; AGED; BASE SEQUENCE; DNA MUTATIONAL ANALYSIS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TELOMERASE; TRANSCRIPTION FACTORS;

EID: 84922010600     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.93     Document Type: Article

References (37)

1. Goff BA, Sainz de la Cuesta R, Muntz HG, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996; 60:412-417.
2. del Carmen MG, Birrer M, Schorge JO. Clear cell carcinoma of the ovary: a review of the literature. Gynecol Oncol 2012;126:481-490.
3. Kuo KT, Mao TL, Jones S, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 2009;174:1597-1601.
4. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010;363:1532-1543.
5. CreasmanWT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95(Suppl 1):S105-S143.
6. Huang CY, Chen CA, Chen YL, et al. Nationwide surveillance in uterine cancer: survival analysis and the importance of birth cohort: 30-year populationbased registry in Taiwan. PLoS ONE 2012;7:e51372.
7. Fadare O, Parkash V, Dupont WD, et al. The diagnosis of endometrial carcinomas with clear cells by gynecologic pathologists: an assessment of interobserver variability and associated morphologic features. Am J Surg Pathol 2012;36:1107-1118.
8. Gilks CB, Oliva E, Soslow RA. Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Am J Surg Pathol 2013;37:874-881.
9. Hoang LN, Han G, McConechy M, et al. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma-diagnostic utility of HNF-1beta and oestrogen receptor. Histopathology 2014;64: 585-596.
10. Fadare O, Renshaw IL, Liang SX. Does the loss of ARID1A (BAF-250a) expression in endometrial clear cell carcinomas have any clinicopathologic significance? A pilot assessment. J Cancer 2012;3:129-136.
11. Allo G, Bernardini MQ, Wu RC, et al. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. Mod Pathol 2014;27:255-261.
12. An HJ, Logani S, Isacson C, et al. Molecular characterization of uterine clear cell carcinoma. Mod Pathol 2004;17:530-537.
13. Gunes C, Rudolph KL. The role of telomeres in stem cells and cancer. Cell 2013;152:390-393.
14. Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer 2008;8:167-179.
15. Widschwendter A, Muller HM, Hubalek MM, et al. Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer. Gynecol Oncol 2004;93:407-416.
16. Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013;339:959-961.
17. Huang FW, Hodis E, Xu MJ, et al. Highly recurrent TERT promoter mutations in human melanoma. Science 2013;339:957-959.
18. Vinagre J, Almeida A, Populo H, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun 2013;4:2185.
19. Landa I, Ganly I, Chan TA, et al. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab 2013;98:E1562-E1566.
20. Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 2013;110: 6021-6026.
21. Wu RC, Ayhan A, Maeda D, et al. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. J Pathol 2014;232:473-481.
22. Huang HN, Lin MC, Huang WC, et al. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma. Mod Pathol 2014;27:983-990.
23. Lee KR, Tavassoli FA, Part J, et al. Surface epithelialstromal tumours, In: Tavassoli FA, Devilee P (eds).World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press: Lyon; 2003, pp 117-145.
24. Maeda D, Mao TL, Fukayama M, et al. Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma. Int J Mol Sci 2010; 11:5120-5128.
25. Yamaguchi K, Mandai M, Toyokuni S, et al. Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent oxidative stress. Clin Cancer Res 2008;14:32-40.
26. Shin-Darlak CY, Skinner AM, Turker MS. A role for Pms2 in the prevention of tandem CC-4 TT substitutions induced by ultraviolet radiation and oxidative stress. DNA Repair (Amst) 2005;4:51-57.
27. Liu T, Wang N, Cao J, et al. The age-and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene 2013 (e-pub ahead of print).
28. Wu S, Huang P, Li C, et al. Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study. Eur Urol 2014;65:274-277.
29. Chan JK, Teoh D, Hu JM, et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 2008;109:370-376.
30. Melo M, da Rocha AG, Vinagre J, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab 2014;99:E754-E765.
31. Morgan RJ Jr, Alvarez RD, Armstrong DK, et al. Ovarian cancer, version 2.2013. J Natl Compr Canc Netw 2013;11:1199-1209.
32. Katagiri A, Nakayama K, Rahman MT, et al. Loss of ARID1A expression is related to shorter progressionfree survival and chemoresistance in ovarian clear cell carcinoma. Mod Pathol 2012;25:282-288.
33. Yamamoto S, Tsuda H, Takano M, et al. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. Virchows Arch 2012;460: 77-87.
34. Rahman MT, Nakayama K, Rahman M, et al. Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma. Cancer 2012;118:2846-2857.
35. Ho CM, Lin MC, Huang SH, et al. PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas. Gynecol Oncol 2009;112:307-313.
36. Rahman M, Nakayama K, Rahman MT, et al. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. Hum Pathol 2012; 43:2197-2206.
37. Abe A, Minaguchi T, Ochi H, et al. PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma. Hum Pathol 2013;44:199-207.